We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Opioid sales increased more than eightfold between 1992 and 2015, according to a new analysis by the FDA that found no clear links between price and volume. Read More
The state declined to refund the federal share of ineligible claims and said all rebate-eligible drugs would be properly invoiced eventually. Read More
A federal judge overturned a $2.5 billion patent infringement verdict, the largest ever in a U.S. patent case, against Gilead Sciences in a dispute with Merck. Read More
Allergan agreed to pay a class of doctors $13.45 million over claims the company artificially maintained the price of Botox through a deal with a potential competitor. Read More
Purdue Pharmaceuticals announced that it will no longer promote its opioid products to doctors and will cut its sales force by more than half. Read More